PRLD

$3.50+0.15 (+4.32%)

Market OpenAs of Mar 17, 4:55 PM UTC

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$3.50
Potential Upside
5%
Whystock Fair Value$3.68
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatm...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$220.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.87
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-99.45%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.95

Recent News

Insider Monkey
Feb 26, 2026

Sana Biotechnology (SANA) Appoints Industry Veteran Brian Piper as New CFO

Sana Biotechnology Inc. (NASDAQ:SANA) is one of the most promising penny stocks under $5 to buy. On February 17, Sana Biotechnology appointed Brian Piper as Executive Vice President and Chief Financial Officer. Brian Piper joined the company with over 25 years of biopharmaceutical experience, most recently serving as CFO of Scorpion Therapeutics and its spin-off, […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jan 28, 2026

Definitive Healthcare And 2 Other Promising Penny Stocks

As the U.S. stock market edges higher with the S&P 500 reaching new milestones, investors are keenly watching for signals from the Federal Reserve and major tech earnings that could influence future trends. Amidst this backdrop, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for those seeking growth at lower price points. Though considered a niche area, these stocks can shine when backed by solid financial health and fundamentals,...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jan 26, 2026

Retail investors in Prelude Therapeutics Incorporated (NASDAQ:PRLD) are its biggest bettors, and their bets paid off as stock gained 12% last week

Key Insights Prelude Therapeutics' significant retail investors ownership suggests that the key decisions are...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Dec 30, 2025

December 2025's Intriguing Stocks Priced Below Estimated Value

As major stock indexes in the United States show mixed performance following two consecutive sessions of losses, investors are keeping a close eye on market movements and economic indicators. In this environment, identifying stocks priced below their estimated value can offer potential opportunities for those looking to capitalize on market inefficiencies.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Dec 30, 2025

3 Promising Penny Stocks With A Market Cap Below $400M

As the holiday-shortened week begins, major U.S. stock indexes have dipped, with technology shares leading the decline and precious metals retreating from recent highs. In such a fluctuating market landscape, identifying stocks with potential for growth can be challenging but rewarding. Penny stocks, often associated with smaller or emerging companies, continue to offer intriguing opportunities for investors willing to explore beyond traditional blue-chip options. These stocks can provide...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
PRLD Stock Analysis & Real-Time Data | Whystock